IMWG consensus on risk stratification in multiple myeloma
Top Cited Papers
- 26 August 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 28 (2), 269-277
- https://doi.org/10.1038/leu.2013.247
Abstract
Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which translates to variable response to treatment and outcome. With the recent increase in treatment armamentarium and the projected further increase in approved therapeutic agents in the coming years, the issue of having some mechanism to dissect this heterogeneity and rationally apply treatment is coming to the fore. A number of robustly validated prognostic markers have been identified and the use of these markers in stratifying patients into different risk groups has been proposed. In this consensus statement, the International Myeloma Working Group propose well-defined and easily applicable risk categories based on current available information and suggests the use of this set of prognostic factors as gold standards in all clinical trials and form the basis of subsequent development of more complex prognostic system or better prognostic factors. At the same time, these risk categories serve as a framework to rationalize the use of therapies.Keywords
This publication has 69 references indexed in Scilit:
- Gene Expression Profiling in Multiple Myeloma—Reporting of Entities, Risk, and Targets in Clinical RoutineClinical Cancer Research, 2011
- Initial genome sequencing and analysis of multiple myelomaNature, 2011
- The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsNature Biotechnology, 2010
- Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and OutcomeClinical Cancer Research, 2010
- Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myelomaLeukemia, 2010
- TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3British Journal of Haematology, 2009
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight reviewLeukemia, 2009
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantationBlood, 2008
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007